Sodium-glucose cotransporter-2 (SGLT2) inhibitors originally developed with the objective of improving the management of type 2 diabetes mellitus (T2DM) by inhibiting glucose reabsorption in the renal proximal tubules (9). Here, SLC5A2 is linked to type 2 diabetes mellitus.